U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C9H9Cl2N3
Molecular Weight 230.094
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CLONIDINE

SMILES

ClC1=CC=CC(Cl)=C1NC2=NCCN2

InChI

InChIKey=GJSURZIOUXUGAL-UHFFFAOYSA-N
InChI=1S/C9H9Cl2N3/c10-6-2-1-3-7(11)8(6)14-9-12-4-5-13-9/h1-3H,4-5H2,(H2,12,13,14)

HIDE SMILES / InChI

Molecular Formula C9H9Cl2N3
Molecular Weight 230.094
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/017407s037lbl.pdf | https://clinicaltrials.gov/ct2/show/NCT02177461 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022331lbl.pdf | https://clinicaltrials.gov/ct2/show/NCT00556959

Clonidine is a centrally acting α2 adrenergic agonist and imidazoline receptor agonist used to treat high blood pressure, attention deficit hyperactivity disorder, anxiety disorders, tic disorders, withdrawal (from either alcohol, opioids, or smoking), migraine, menopausal flushing, diarrhea, and certain pain conditions. Clonidine treats high blood pressure by stimulating α2 receptors in the brain, which decreases peripheral vascular resistance, lowering blood pressure. It has specificity towards the presynaptic α2 receptors in the vasomotor center in the brainstem. This binding decreases presynaptic calcium levels, thus inhibiting the release of norepinephrine (NE). It has also been proposed that the antihypertensive effect of clonidine is due to agonism on the I1 receptor (imidazoline receptor), which mediates the sympatho-inhibitory actions of imidazolines to lower blood pressure. Clonidines mechanism of action in the treatment of ADHD is to increase noradrenergic tone in the prefrontal cortex (PFC) directly by binding to postsynaptic α2A adrenergic receptors and indirectly by increasing norepinephrine input from the locus coeruleus. Clonidine indicated in the treatment of hypertension. Clonidine hydrochloride tablets may be employed alone or concomitantly with other antihypertensive agents. The US Food and Drug Administration (FDA) has approved clonidine for the treatment of attention deficit hyperactivity disorder (ADHD), under the trade name of Kapvay alone or with stimulants in 2010, for pediatric patients aged 6–17 years.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CATAPRES-TTS-1

Approved Use

INDICATIONS & USAGE Clonidine hydrochloride tablets, USP are indicated in the treatment of hypertension. Clonidine hydrochloride tablets, USP may be employed alone or concomitantly with other antihypertensive agents.

Launch Date

1984
Primary
KAPVAY

Approved Use

INDICATIONS AND USAGE. KAPVAY® is a centrally acting alpha2-adrenergic agonist indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to stimulant medications

Launch Date

2009
Primary
CATAPRES-TTS-1

Approved Use

INDICATIONS & USAGE Clonidine hydrochloride tablets, USP are indicated in the treatment of hypertension. Clonidine hydrochloride tablets, USP may be employed alone or concomitantly with other antihypertensive agents.

Launch Date

1984
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
443 pg/mL
0.1 mg single, oral
dose: 0.1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLONIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
7313 pg × h/mL
0.1 mg single, oral
dose: 0.1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLONIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
12.57 h
0.1 mg single, oral
dose: 0.1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLONIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
0.25 mg 2 times / day multiple, oral
Studied dose
Dose: 0.25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.25 mg, 2 times / day
Co-administed with::
Methylphenidate(54 mg/day)
Sources: Page: nda/2010/022331Orig1s001.pdf - p.139
unhealthy, 13 years
n = 1
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: 13 years
Sex: M
Population Size: 1
Sources: Page: nda/2010/022331Orig1s001.pdf - p.139
Other AEs: Suicide attempt...
Other AEs:
Suicide attempt
Sources: Page: nda/2010/022331Orig1s001.pdf - p.139
2 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2 mg, 3 times / day
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Condition: hypertension
Age Group: adult
Population Size: 1
Sources:
0.2 mg 2 times / day multiple, oral
Recommended
Dose: 0.2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 2 times / day
Co-administed with::
Amphetamine
Methylphenidate(54 mg/day)
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
unhealthy, median age 10 years
n = 102
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: median age 10 years
Sex: M+F
Population Size: 102
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
Disc. AE: Bradyphrenia...
AEs leading to
discontinuation/dose reduction:
Bradyphrenia (1%)
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
0.1 mg 2 times / day multiple, oral
Recommended
Dose: 0.1 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.1 mg, 2 times / day
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
unhealthy, median age 9 years
n = 76
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: median age 9 years
Sex: M+F
Population Size: 76
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
Disc. AE: Somnolence, Fatigue...
AEs leading to
discontinuation/dose reduction:
Somnolence (3.9%)
Fatigue (2.6%)
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
0.2 mg 2 times / day multiple, oral
Recommended
Dose: 0.2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 2 times / day
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
unhealthy, median age 9 years
n = 78
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: median age 9 years
Sex: M+F
Population Size: 78
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
Disc. AE: Somnolence, Fatigue...
AEs leading to
discontinuation/dose reduction:
Somnolence (6.4%)
Fatigue (5.1%)
Constipation (1.3%)
Vomiting (1.3%)
Electrocardiogram QT prolonged (1.3%)
Rash (1.3%)
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
0.1 mg 2 times / day steady, oral
Dose: 0.1 mg, 2 times / day
Route: oral
Route: steady
Dose: 0.1 mg, 2 times / day
Sources:
unhealthy
n = 22
Health Status: unhealthy
Condition: Fecal Incontinence
Population Size: 22
Sources:
Other AEs: Dry mouth, Drowsiness...
Other AEs:
Dry mouth (below serious, 16 patients)
Drowsiness (below serious, 5 patients)
Lightheadedness (below serious, 6 patients)
Fatigue (below serious, 8 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Suicide attempt
0.25 mg 2 times / day multiple, oral
Studied dose
Dose: 0.25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.25 mg, 2 times / day
Co-administed with::
Methylphenidate(54 mg/day)
Sources: Page: nda/2010/022331Orig1s001.pdf - p.139
unhealthy, 13 years
n = 1
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: 13 years
Sex: M
Population Size: 1
Sources: Page: nda/2010/022331Orig1s001.pdf - p.139
Bradyphrenia 1%
Disc. AE
0.2 mg 2 times / day multiple, oral
Recommended
Dose: 0.2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 2 times / day
Co-administed with::
Amphetamine
Methylphenidate(54 mg/day)
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
unhealthy, median age 10 years
n = 102
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: median age 10 years
Sex: M+F
Population Size: 102
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
Fatigue 2.6%
Disc. AE
0.1 mg 2 times / day multiple, oral
Recommended
Dose: 0.1 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.1 mg, 2 times / day
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
unhealthy, median age 9 years
n = 76
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: median age 9 years
Sex: M+F
Population Size: 76
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
Somnolence 3.9%
Disc. AE
0.1 mg 2 times / day multiple, oral
Recommended
Dose: 0.1 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.1 mg, 2 times / day
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
unhealthy, median age 9 years
n = 76
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: median age 9 years
Sex: M+F
Population Size: 76
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
Constipation 1.3%
Disc. AE
0.2 mg 2 times / day multiple, oral
Recommended
Dose: 0.2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 2 times / day
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
unhealthy, median age 9 years
n = 78
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: median age 9 years
Sex: M+F
Population Size: 78
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
Electrocardiogram QT prolonged 1.3%
Disc. AE
0.2 mg 2 times / day multiple, oral
Recommended
Dose: 0.2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 2 times / day
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
unhealthy, median age 9 years
n = 78
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: median age 9 years
Sex: M+F
Population Size: 78
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
Rash 1.3%
Disc. AE
0.2 mg 2 times / day multiple, oral
Recommended
Dose: 0.2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 2 times / day
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
unhealthy, median age 9 years
n = 78
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: median age 9 years
Sex: M+F
Population Size: 78
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
Vomiting 1.3%
Disc. AE
0.2 mg 2 times / day multiple, oral
Recommended
Dose: 0.2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 2 times / day
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
unhealthy, median age 9 years
n = 78
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: median age 9 years
Sex: M+F
Population Size: 78
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
Fatigue 5.1%
Disc. AE
0.2 mg 2 times / day multiple, oral
Recommended
Dose: 0.2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 2 times / day
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
unhealthy, median age 9 years
n = 78
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: median age 9 years
Sex: M+F
Population Size: 78
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
Somnolence 6.4%
Disc. AE
0.2 mg 2 times / day multiple, oral
Recommended
Dose: 0.2 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.2 mg, 2 times / day
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
unhealthy, median age 9 years
n = 78
Health Status: unhealthy
Condition: attention deficit hyperactivity disorder
Age Group: median age 9 years
Sex: M+F
Population Size: 78
Sources: Page: nda/2010/022331Orig1s001.pdf - p.108
Dry mouth below serious, 16 patients
0.1 mg 2 times / day steady, oral
Dose: 0.1 mg, 2 times / day
Route: oral
Route: steady
Dose: 0.1 mg, 2 times / day
Sources:
unhealthy
n = 22
Health Status: unhealthy
Condition: Fecal Incontinence
Population Size: 22
Sources:
Drowsiness below serious, 5 patients
0.1 mg 2 times / day steady, oral
Dose: 0.1 mg, 2 times / day
Route: oral
Route: steady
Dose: 0.1 mg, 2 times / day
Sources:
unhealthy
n = 22
Health Status: unhealthy
Condition: Fecal Incontinence
Population Size: 22
Sources:
Lightheadedness below serious, 6 patients
0.1 mg 2 times / day steady, oral
Dose: 0.1 mg, 2 times / day
Route: oral
Route: steady
Dose: 0.1 mg, 2 times / day
Sources:
unhealthy
n = 22
Health Status: unhealthy
Condition: Fecal Incontinence
Population Size: 22
Sources:
Fatigue below serious, 8 patients
0.1 mg 2 times / day steady, oral
Dose: 0.1 mg, 2 times / day
Route: oral
Route: steady
Dose: 0.1 mg, 2 times / day
Sources:
unhealthy
n = 22
Health Status: unhealthy
Condition: Fecal Incontinence
Population Size: 22
Sources:
Overview

Overview

Drug as perpetrator​Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Letter: Dementia associated with clonidine therapy.
1975 Mar 15
Clonidine-Induced Heat-Shock Protein Expression in Rat Aorta.
1998 Apr
Can a dose of 2microg.kg(-1) caudal clonidine cause respiratory depression in neonates?
1999
High thoracic epidural anesthesia, but not clonidine, attenuates the perioperative stress response via sympatholysis and reduces the release of troponin T in patients undergoing coronary artery bypass grafting.
1999 Apr
Cocaine-induced hypertension: role of the peripheral sympathetic system.
1999 Aug
Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic mice.
1999 Mar
Anticonvulsants for soman-induced seizure activity.
1999 Mar-Apr
Acute detoxification of opioid-addicted patients with naloxone during propofol or methohexital anesthesia: a comparison of withdrawal symptoms, neuroendocrine, metabolic, and cardiovascular patterns.
2000 Apr
Alpha-2 adrenergic receptor agonists block stress-induced reinstatement of cocaine seeking.
2000 Aug
Low-dose clonidine and neostigmine prolong the duration of intrathecal bupivacaine-fentanyl for labor analgesia.
2000 Feb
A direct search procedure to optimize combinations of epidural bupivacaine, fentanyl, and clonidine for postoperative analgesia.
2000 Feb
Relative potency of epidural to intrathecal clonidine differs between acute thermal pain and capsaicin-induced allodynia.
2000 Jan
The influence of indomethacin on the acth secretion induced by central stimulation of adrenergic receptors.
2000 Jun
Galanin/alpha2-receptor interactions in central cardiovascular control.
2000 Jun 8
Hypoxic-ischaemic brain damage in immature rats: effects of adrenoceptor modulation.
2001
[Potentiation of local anesthesia in endonasal surgery].
2001
P75-expressing elements are necessary for anti-allodynic effects of spinal clonidine and neostigmine.
2001
Oops--wrong dose of epidural clonidine in children!
2001 Apr
Alpha2 adrenergic receptors and the central control of breathing in the cane toad, Bufo marinus.
2001 Apr
Sodium-induced rise in blood pressure is suppressed by androgen receptor blockade.
2001 Apr
Some behavioural effects of antidepressant drugs are time-dependent.
2001 Feb
Baclofen versus clonidine in the treatment of opiates withdrawal, side-effects aspect: a double-blind randomized controlled trial.
2001 Feb
Differential effects of clonidine, dopamine, dobutamine, and dopexamine on basal and acid-stimulated mucosal blood flow in the rat stomach.
2001 Feb
Nitric oxide and central antihypertensive drugs: one more difference between catecholamines and imidazolines.
2001 Feb
Mortality after coronary artery occlusion in different models of cardiac hypertrophy in rats.
2001 Feb
Effectiveness of apraclonidine 1% in preventing intraocular pressure rise following macular hole surgery.
2001 Feb
Immunomodulatory effect of xylazine, an alpha(2) adrenergic agonist, on rat spleen cells in culture.
2001 Feb 1
Noradrenergic dysfunction in the prefrontal cortex in depression: an [15O] H2O PET study of the neuromodulatory effects of clonidine.
2001 Feb 15
Antagonistic effects of selective alpha1-adrenoceptor antagonists MDL73005EF and tamsulosin and partial agonists clonidine and tizanidine in rat thoracic aorta and rabbit iliac artery.
2001 Jan
Apical uptake of organic cations by human intestinal Caco-2 cells: putative involvement of ASF transporters.
2001 Jan
Effect of chronic morphine treatment on alpha(2)-adrenoceptor mediated autoinhibition of transmitter release from sympathetic varicosities of the mouse vas deferens.
2001 Jan
Chronic treatment with reboxetine by osmotic pumps facilitates its effect on extracellular noradrenaline and may desensitize alpha(2)-adrenoceptors in the prefrontal cortex.
2001 Jan
Use of trifluoroperazine isolates a [(3)H]Ifenprodil binding site in rat brain membranes with the pharmacology of the voltage-independent ifenprodil site on N-methyl-D-aspartate receptors containing NR2B subunits.
2001 Jan
The noradrenergic alpha2 agonist clonidine modulates behavioural and neuroanatomical correlates of human attentional orienting and alerting.
2001 Jan
Effects of antisense to the (alpha)2A-adrenoceptors administered into the region of the locus ceruleus on behaviors in plus-maze and sexual behavior tests in sham-operated and castrated male rats.
2001 Jan 15
Premedication modifies the quality of sedation with propofol during regional anesthesia.
2001 Mar
Noradrenergic modulation of calcium currents and synaptic transmission in the olfactory bulb of Xenopus laevis tadpoles.
2001 Mar
Ultrasonic vocalizations of preweanling rats: involvement of both alpha(2)-adrenoceptor and kappa-opioid receptor systems.
2001 Mar
The analgesic interaction between intrathecal clonidine and glutamate receptor antagonists on thermal and formalin-induced pain in rats.
2001 Mar
Activation of beta-adrenoceptors opens calcium-activated potassium channels in astroglial cells.
2001 Mar
Gelatin microspheres crosslinked with D,L-glyceraldehyde as a potential drug delivery system: preparation, characterisation, in vitro and in vivo studies.
2001 Mar 14
Morphine and clonidine activate different K+ channels on rat amygdala neurons.
2001 Mar 9
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/018891s028lbl.pdf
Oral Initial Dose 0.1 mg tablet twice daily (morning and bedtime). Elderly patients may benefit from a lower initial dose Maintenance Dose Further increments of 0.1 mg per day may be made at weekly intervals if necessary until the desired response is achieved. Taking the larger portion of the oral daily dose at bedtime may minimize transient adjustment effects of dry mouth and drowsiness. The therapeutic doses most commonly employed have ranged from 0.2 mg to 0.6 mg per day given in divided doses. Studies have indicated that 2.4 mg is the maximum effective daily dose, but doses as high as this have rarely been employed. Transdermal: once every 7 days to a hairless area of intact skin on the upper outer arm or chest.
Route of Administration: Other
Neural membranes (P2 fractions) were prepared from the prefrontal cortex of human brains obtained at autopsy. Specific Clonidine binding was measured in 0.55 mL aliquots (50 mM Tris HCl, pH 7.5) of the neural membranes, which were incubated with [3H]RX821002 (1 nM) for 30 min at 25 °C in the absence or presence of the Clonidine (10^-12 M to 10^-3 M, 10 concentrations). Specific binding was determined and plotted as a function of the compound concentration. Incubations were terminated by diluting the samples with 5 mL of ice-cold Tris incubation buffer (4 °C). Membrane-bound [3H]RX821002 was separated by vacuum filtration through Whatman GF/C glass fiber filters. Then the filters were rinsed twice with 5 mL of incubation buffer and transferred to minivials containing 3 mL of OptiPhase “HiSafe” II cocktail and counted for radioactivity by liquid scintillation spectrometry.
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:19:53 GMT 2023
Edited
by admin
on Sat Dec 16 16:19:53 GMT 2023
Record UNII
MN3L5RMN02
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CLONIDINE
HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
CLONIDINE [VANDF]
Common Name English
ST-155-BS
Code English
CLONIDINE [HSDB]
Common Name English
CLONIDINE [USP-RS]
Common Name English
CLONIDINE EXTENDED RELEASE
Common Name English
CLONIDINE [MI]
Common Name English
CLONIDINE [USAN]
Common Name English
CLONIDINE [JAN]
Common Name English
Clonidine [WHO-DD]
Common Name English
CATARPRES-TTS
Brand Name English
CLONIDINE [MART.]
Common Name English
CLONIDINE [ORANGE BOOK]
Common Name English
2-[(2,6-Dichlorophenyl)imino]imidazolidine
Systematic Name English
clonidine [INN]
Common Name English
CLONIDINE [USP MONOGRAPH]
Common Name English
Classification Tree Code System Code
WHO-ATC C02LC51
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
WHO-ATC S01EA04
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
NDF-RT N0000009918
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
WHO-VATC QC02LC01
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
WHO-ATC N02CX02
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
WHO-VATC QC02LC51
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
WHO-VATC QN02CX02
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
NCI_THESAURUS C29709
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
FDA ORPHAN DRUG 425614
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
NDF-RT N0000175554
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
FDA ORPHAN DRUG 34388
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
WHO-VATC QC02AC01
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
WHO-VATC QS01EA04
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
LIVERTOX NBK548329
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
WHO-ATC C02AC01
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
WHO-ATC C02LC01
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
Code System Code Type Description
NCI_THESAURUS
C380
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
PRIMARY
EPA CompTox
DTXSID6022846
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
PRIMARY
DRUG BANK
DB00575
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
PRIMARY
RXCUI
2599
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
PRIMARY RxNorm
FDA UNII
MN3L5RMN02
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
PRIMARY
CAS
4205-90-7
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
PRIMARY
ECHA (EC/EINECS)
224-119-4
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
PRIMARY
MESH
D003000
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
PRIMARY
IUPHAR
516
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
PRIMARY
DAILYMED
MN3L5RMN02
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
PRIMARY
SMS_ID
100000084529
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
PRIMARY
PUBCHEM
2803
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
PRIMARY
LACTMED
Clonidine
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
PRIMARY
INN
2624
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
PRIMARY
WIKIPEDIA
CLONIDINE
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
PRIMARY
USAN
U-77
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
PRIMARY
ChEMBL
CHEMBL134
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
PRIMARY
DRUG CENTRAL
704
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
PRIMARY
MERCK INDEX
m3650
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
PRIMARY Merck Index
RS_ITEM_NUM
1140393
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
PRIMARY
HSDB
3040
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
PRIMARY
CHEBI
46631
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
PRIMARY
EVMPD
SUB06730MIG
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
PRIMARY
CHEBI
3757
Created by admin on Sat Dec 16 16:19:55 GMT 2023 , Edited by admin on Sat Dec 16 16:19:55 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> AGONIST
Ki
TARGET -> AGONIST
SHORT-ACTING
TARGET -> AGONIST
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
TARGET -> AGONIST
SALT/SOLVATE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY